Literature DB >> 33603988

How to Assess Founder Effect in Patients with Congenital Factor XIII Deficiency.

Hojat Shahraki1, Akbar Dorgalaleh1, Majid Fathi2, Shadi Tabibian1, Shahram Teimourian3, Hasan Mollanoori3, Alireza Khiabani4, Farhad Zaker1.   

Abstract

Congenital factor XIII (FXIII) deficiency is an extremely rare bleeding disorder (RBD) with estimated prevalence of one per 2 million in the general population. The disorder causes different clinical manifestations such as intracranial hemorrhage (ICH), recurrent miscarriage, umbilical cord bleeding, etc. High incidence of the disorder might be due to founder effect. To assess founder effect, haplotype analysis is an important step. For this purpose, suitable and reliable genetic markers such as microsatellites (Hum FXIIIA01 and HumFXIIIA02) and single nucleotide polymorphisms (SNP) are suggested. In the present study we tried to describe evaluation of founder effect in patients with congenital FXIII deficiency via haplotype analysis using suitable genetic markers.
Copyright © 2020 Tehran University of Medical Sciences.

Entities:  

Keywords:  Factor XIII deficiency; Founder effect; Genetic markers; Intracranial hemorrhage

Year:  2020        PMID: 33603988      PMCID: PMC7876424          DOI: 10.18502/ijhoscr.v14i4.4480

Source DB:  PubMed          Journal:  Int J Hematol Oncol Stem Cell Res        ISSN: 2008-2207


Introduction

Factor XIII (FXIII) deficiency is a rare inherited disorders with an incidence of one per 2 million. The disorder is higher in some regions like Iran, Pakistan, Tunisia, Indian, etc.  [1], [2] . Patients with FXIII deficiency have different clinical manifestations like recurrent and delayed bleeding, intracerebral hemorrhage (ICH), umbilical cord blood (UCB), defected wound healing and recurrent miscarriages  [3],[4] . There are specific and common mutations of factor XIII gene in different geographic areas. Due to autosomal recessive pattern of inheritance and rate of consanguineous marriages, disease causing mutations may inherited to children by their parents[5]. On the other words, the presence of a same mutation in different non-consanguineous families in a particular area may indicate a common ancestor or a founder effect. Founder effect causing mutation is called founder mutation. For example, Trp187Arg is a suitable example for FXIII deficiency associated with founder mutation in southeast Iran. These types of mutations usually occur in one or more founders of a new and different population and are inherited to next generations, which finally make a great alteration in DNA. In other words, pathogenic alleles will be displayed in next generations in homozygote form and probably founder effect could be the reason of high incidence disorder [6],[7] . For assessment of founder effect if: 1) candidate microsatellites and single nucleotide polymorphisms (SNPs) are meaningfully different in patient and control groups, 2) a unique haplotype is observed in the majority of the patients, these can indicate genetic linkage between microsatellites and polymorphisms with causative mutation [8]-[10] . Our goal in the present study was to describe how founder effect influences FXIII deficiency in areas with particular mutation by using haplotype analysis and suitable genetic markers. Diagnosis of factor XIII deficiency Routine coagulation tests like bleeding time, prothrombin time, activated partial thromboplastin time, fibrinogen level and platelets count are normal[11]. The primary and the most commonly used test is clot solubility test. This is a qualitative test and is positive only in patients with a very low of FXIII [1]-[12] . Measuring FXIII activity is a decisive diagnosis[   13 ]. Commercial ELISA kits are available for measuring of FXIII-A2B2, FXIII-A and FXIII-B antigenic levels[   14 ]. Finally, genetic analysis can help to find associated mutations of FXIII gene. Carrier detection is very important to prevent marriage of these patients and to recognize FXIII suspected individuals in haplotype aspects  [15], [16] . More than 170 mutations have been identified within F13A and F13B genes, most belongs to F13A subunit  [17],[18] . Sanger sequencing is the most common DNA sequencing method, but next-generation sequencing (NGS) is a more advanced sequencing technology, which can increase the rate of mutation detection  [16], [19] . Founder effect Founder effect is one of the important topics in population genetics and it is one of the ways that nature uses to generate new species from primary populations  [10], [20] . In a simple word, sometimes, a few number of a large population immigrate to specific locations. Others cannot enter to these population to make change in their genetic pool that leads to lower genetic diversity and occurring of defected pathogenic mutation that is actually called founder effect [   10 ]. Over the time, new populations genetically and phenotypically become thoroughly differentiated from the primary population. Founder effect causing mutation is called founder mutation. Founder effect in congenital factor XIII deficiency There are F13A common mutations in the different geographic areas. For example, Trp187Arg and Arg77His are common in Iran, Ser295Arg and c.2045G>A in Pakistan, c.869insC in Tunisia, Arg77Cys in Switzerland, and Arg661X in Finland  [3], [7], [21]-[33] . In India, IVS1 A246G polymorphisms seems to be the most common FXIII polymorphisms [   34 ]. The IVS5-1G>A mutation was observed in European countries, including Poland, Czech Republic, Turkish, Greek, UK, Macedonia and the Netherlands  [7], [30], [35], [36] . According to the inheritance pattern of mutation, disease-associated mutations may happen in previous generations. Presence of a same mutation in different non-consanguineous families in a special area may show common ancestor. For example, Trp187Arg is a suitable example for FXIII deficiency associated with founder mutation in southeast Iran[37]. These types of mutations usually occur in one or more founders of a new and different population and are inherited to next generation, and finally make great alterations in DNA. In other words, pathogenic alleles will be displayed in next generations in homozygote forms. One important population example is congenital FXI deficiency in Ashkenazi Jews [   38 ]. How to evaluate association of founder effect and FXIII deficiency We can use haplotype analysis in order to evaluate founder effect which is caused by inbreeding in populations of a certain area [9],[39] . Haplotype is a combination of alleles in different locus of a chromosome that inherit together. In simple word, haplotype is a set of a mononucleotide polymorphisms like SNPs, microsatellites, variable number tandem repeats (VNTRs) on one chromosome of homologous chromosomes  [40],[41] . These markers are sequences of DNA and they inherit together due to their closeness to disease-associated gene, therefore if an individual or a group possesses a set of linked markers, the presence of disease-associated gene in their genome is assumable. Therefore, haplotype analysis via SNP, microsatellite and VNTRs can be used to assess the association of founder effect with specific and considered mutation as the most incident type of FXIII deficiency causing mutation in particular region[42],[43]. It's important that selected polymorphic markers should be informative and be close to disease-causing gene to achieve the best results  [44], [45] . First step: Diagnosis of FXIII deficiency -Providing questionnaires, including individual's characteristics such as age, gender, city of residence, family history, clinical symptoms -Sample collection -Routine coagulation tests: At first all FXIII deficiency suspected individuals have to be examined by common coagulation tests like bleeding time (BT), prothrombin time (PT), activated partial thromboplastin time (PTT), platelet count and fibrinogen level. Those patients with low FXIII level who showed a significant decrease (1 to 2%) should enter to molecular laboratory phase (Figure 1)[   2 ].
Figure 1

How to diagnose FXIII deficiency suspected individuals

How to diagnose FXIII deficiency suspected individuals BT: Bleeding Time, PT: Prothrombin Time, PTT: Activated Partial Thromboplastin Time Second step: Detection of molecular defect in patients with congenital FXIII deficiency - Bioinformatics studies: To find FXIII gene in NCBI data bank. - DNA extraction -Quantitative and qualification assessment of extracted DNA -Polymerase chain reaction-Restriction fragment length polymorphisms (PCR-RFLP): To select suitable restriction enzymes, after bioinformatics analysis based on candidate enzyme selected, different fragments of DNA are observable on electrophoresis gel, which indicates homozygote, heterozygote and normal gene (Table 1)  [46]-[48] .
Table 1

Characteristics of important features most common mutation of congenital factor XIII deficiency

Most common mutation Origin of patient Chromosome location Genotype Type Domain Gene subunit Functional information References
Trp187ArgIranExon 4HomozygousMissenseCoreFXIII A-subunitSteric clashes of arginine with side chains(3, 6, 21, 22, 37, 49)
Arg77HisIranExon 3Homozygousb-sandwichMissenseFXIII A-subunitDisruption of most H-bonds(2, 21, 22, 47, 49)
Ser295ArgPakistanExon 7HomozygousMissenseCoreFXIII A-subunitIncorrect folding resulting in an unstable FXIIIA polypeptide(7, 24-27)
c.2045G>APakistanExon 14HomozygousSplicingBarrel 2FXIII A-subunitProbably splicing defect(7, 25-27)
Arg77CysSwitzerlandExon 3HomozygousMissenseb-sandwichFXIII A-subunitDisruption of most H-bonds(7, 30)
c.869insCTunisiaExon 7HomozygousFrameshiftCoreFXIII A-subunitStop after 8 altered amino acid(26, 28, 29)
Arg661XFinlandExon 14HeterozygousNonsenseBarrel 2FXIII A-subunitDecrease of FXIII mRNA levels(31-33)
IVS5-1G>AEuropean Countries: Netherland, Poland, UK, Czech Republic, Macrdonia, Greek, German and TurkishIntron 5HomozygousSplicingintronicFXIII A-subunitEffect on RNA splicing(1, 2, 7, 30, 35, 36)
A246GIndiaIntron 14HeterozygousSplicingintronicFXIII A-subunitProbably splicing defect(34)
Characteristics of important features most common mutation of congenital factor XIII deficiency Third step: selection of suitable microsatellites Microsatellites are highly polymorphic and repetitive DNA sequences. These sequences are 2 to 6 base pair repeats that place along DNA [   50 ]. Microsatellites are highly polymorphic and mutation prone. Because of microsatellite uniqueness in different populations and high number of them in the genome, they can be used as informative markers to investigate genetic association among human ethnics, population genetics and haplotype analysis [39],[51] . There is a criterion named polymorphic informative content (PIC), which indicates allele frequency in the population and relates with mean repeat length. PIC < 0.7 represents that microsatellite is informative and this is important in microsatellite option [45], [52] . -Candidate microsatellite: based on previous studies and bioinformatics analysis in NCBI databank and FXIII Database, 2 microsatellites could be selected in F13A gene (Table 2).
Table 2

Features of Hum FXIII A01 and Hum FXIII A02 microsatellites

Microsatellite Human FXIIIA01 (FXIIIA01) Human FXIIIA02 (FXIIIA02)
Repeat sequenceAAAGAC
Chromosomal location6p24-256p24-25
Gene bank accessionM21986-
Expected range of allele281-331204-236
PCR primers5΄-TTTTCTCTGCCTTCCCATGT-3΄3΄-ATGCCATGCCAGATTAGAAA-5΄5΄-GAGGTTGCACTCCAGCCTTT-3΄3΄-CCCCCAGTGCAGTGTTTTAT-5΄
Primer concentration0.1 Micromolar0.1 Micromolar

* No accession number was reported for this STR and it was mentioned in article 29.

-Microsatellite Hum FXIII A01 has repeated sequence of AAAG in chromosomal location of 6p24-25 and in 5`UTR(-2775/ATG) region  [44], [53] . -Microsatellite Hum FXIII A02 has repeated sequence of AC (poly AC) in chromosomal location of 6p24-25 and in intron 8 region [   29 ]. For visiting the most practical microsatellites in details, go to http://www.cstl.nist.gov/biotech/strbase. - DNA extraction -Quantitative and qualitative assessment of extracted DNA -PCR along labeled primers with fluorescent substance (FAM) - Capillary electrophoresis - Data analysis using Gene marker software Fourth step: Selection of suitable SNPs for haplotype analysis SNPs occur with frequency of 1% in general population and they span all the human genome, because of this, these markers are widely used in diagnosis of different cancers and congenital genetic disorders  [40], [54], [55] . -Candidate SNPs: SNPs are selected after bioinformatics analysis in NCBI database. Candidate SNPs should be verified by Hapmap project, Cluster, 1000 genomes project and frequency databases. Furthermore, these SNPs are mostly locate in FXIIIA gene (6:6144077-6320590). It is better to select SNPS with global minor allele frequency (Global MAF) near to 0.5 to have fewer differences between SNPs allele incidence (Table 3)  [9], [40], [42] .
Table 3

Features of candidate Single Nucleotide Polymorphism (SNPs)

SNP rs3024317 rs4960181 rs63778360 rs7757882 rs1781794 rs1674044
Number123456
Chromosomal location6:63191466:62690656:61501326:61899676:62415476:6310481
Hap map
Intron Site33141162
Frequency
Global MAF0.46880.48540.48420.45530.48880.4535
1000 G
Cluster
- DNA extraction - Qualitative and quantitative assessment of extracted DNA - PCR - Sequencing or PCR-RFLP - Data analysis by CLC sequencer and Chromas software Fifth step: Haplotype analysis After data analysis, we have to determine similarity of haplotypes in FXIII deficiency patients. Generally microsatellites are more reliable markers than SNPs[9],[44],[45]. On the other hand, larger number of genetic markers in a study results in more reliable and informative results. The important point is that in haplotype analysis, shorter distances between genetic markers and considered mutations will achieve to more reliable results. We can differentiate haplotypes by comparing results of patients and normal individuals[56]. Schematic figure of chromosomal location of candidate SNPs and STRs for FXIII haplotype analysis are shown in Figure 2.
Figure 2

Schematic figure of chromosomal location of candidate microsatellites and SNPs of F13A gene

Features of Hum FXIII A01 and Hum FXIII A02 microsatellites * No accession number was reported for this STR and it was mentioned in article 29. Features of candidate Single Nucleotide Polymorphism (SNPs) Schematic figure of chromosomal location of candidate microsatellites and SNPs of F13A gene

CONCLUSION

When we are evaluating impact of founder effect in congenital FXIII deficiency, we have to notice that if: -Candidate microsatellites and SNPs were meaningfully different in patients and control groups -A unique haplotype was observed in most of the patients These can indicate genetic linkage between microsatellites and polymorphisms with considered mutation and subsequently this genetic linkage can imply a kind of founder effect for the disease, which means that previous generations increased FXIII deficiency via consanguineous marriage. Generally, it is considered some circumstances like consanguineous marriage; ethnic and place of residence can prominently increase pathogenic mutations, founder effect and subsequently raise FXIII deficiency. Evaluating association of founder effect with FXIII deficiency by step-by-step diagnostic algorithm

Funding

This study was supported by Grant No. 94-05-31-27408 from Iran University of Medical Sciences.
  52 in total

Review 1.  Microsatellites within genes: structure, function, and evolution.

Authors:  You-Chun Li; Abraham B Korol; Tzion Fahima; Eviatar Nevo
Journal:  Mol Biol Evol       Date:  2004-02-12       Impact factor: 16.240

Review 2.  Arg77His and Trp187Arg are the most common mutations causing FXIII deficiency in Iran.

Authors:  Peyman Eshghi; Nader Cohan; Manigeh Lak; Majid Naderi; Flora Peyvandi; Marzia Menegatti; Mehran Karimi
Journal:  Clin Appl Thromb Hemost       Date:  2011-12-06       Impact factor: 2.389

Review 3.  Genetic diagnosis of haemophilia and other inherited bleeding disorders.

Authors:  F Peyvandi; G Jayandharan; M Chandy; A Srivastava; S M Nakaya; M J Johnson; A R Thompson; A Goodeve; I Garagiola; S Lavoretano; M Menegatti; R Palla; M Spreafico; L Tagliabue; R Asselta; S Duga; P M Mannucci
Journal:  Haemophilia       Date:  2006-07       Impact factor: 4.287

4.  Tetranucleotide repeat polymorphism at the human coagulation factor XIII A subunit gene (F13A1).

Authors:  M H Polymeropoulos; D S Rath; H Xiao; C R Merril
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

5.  Challenges in implementation of ISTH diagnostic algorithm for diagnosis and classification of factor XIII deficiency in Iran.

Authors:  A Dorgalaleh; Y Farshi; S H Alizadeh; M Naderi; S H Tabibian; A Kazemi; S Hosseini
Journal:  J Thromb Haemost       Date:  2015-07-15       Impact factor: 5.824

6.  Evaluation of 13 short tandem repeat loci for use in personal identification applications.

Authors:  H A Hammond; L Jin; Y Zhong; C T Caskey; R Chakraborty
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

Review 7.  Factor XIII Deficiency.

Authors:  Mehran Karimi; Zsuzsanna Bereczky; Nader Cohan; László Muszbek
Journal:  Semin Thromb Hemost       Date:  2009-07-13       Impact factor: 4.180

Review 8.  Blood coagulation factor XIII and factor XIII deficiency.

Authors:  Akbar Dorgalaleh; Jamal Rashidpanah
Journal:  Blood Rev       Date:  2016-06-16       Impact factor: 8.250

9.  A point mutation in an invariant splice acceptor site results in a decreased mRNA level in a patient with severe coagulation factor XIII subunit A deficiency.

Authors:  P Vreken; R W Niessen; M Peters; M C Schaap; J G Zuithoff-Rijntjes; A Sturk
Journal:  Thromb Haemost       Date:  1995-08       Impact factor: 5.249

Review 10.  Current understanding in diagnosis and management of factor XIII deficiency.

Authors:  M Naderi; A Dorgalaleh; Sh Tabibian; Sh Alizadeh; P Eshghi; Gh Solaimani
Journal:  Iran J Ped Hematol Oncol       Date:  2013-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.